DK1715890T3 - CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati - Google Patents

CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati

Info

Publication number
DK1715890T3
DK1715890T3 DK05713358T DK05713358T DK1715890T3 DK 1715890 T3 DK1715890 T3 DK 1715890T3 DK 05713358 T DK05713358 T DK 05713358T DK 05713358 T DK05713358 T DK 05713358T DK 1715890 T3 DK1715890 T3 DK 1715890T3
Authority
DK
Denmark
Prior art keywords
diabetic nephropathy
microalbuminuria
ctgf
therapy
patients
Prior art date
Application number
DK05713358T
Other languages
Danish (da)
English (en)
Inventor
Allan Flyvbjerg
Guangjie Guo
David Y Liu
Thomas B Neff
Noelynn A Oliver
William R Usinger
Qingjian Wang
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of DK1715890T3 publication Critical patent/DK1715890T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DK05713358T 2004-02-11 2005-02-11 CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati DK1715890T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20
PCT/US2005/004367 WO2005077413A1 (fr) 2004-02-11 2005-02-11 Traitement de la nephropathie diabetique ciblant le facteur de croissance des tissus conjonctifs (ctgf)

Publications (1)

Publication Number Publication Date
DK1715890T3 true DK1715890T3 (da) 2008-11-17

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05713358T DK1715890T3 (da) 2004-02-11 2005-02-11 CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati

Country Status (15)

Country Link
US (2) US20050214294A1 (fr)
EP (2) EP1977762A1 (fr)
CN (1) CN101884789A (fr)
AT (1) ATE400297T1 (fr)
AU (1) AU2005212371B2 (fr)
CA (1) CA2555789A1 (fr)
DE (1) DE602005008013D1 (fr)
DK (1) DK1715890T3 (fr)
ES (1) ES2311973T3 (fr)
HK (1) HK1095762A1 (fr)
IL (1) IL177437A (fr)
NZ (1) NZ549784A (fr)
PL (1) PL1715890T3 (fr)
PT (1) PT1715890E (fr)
WO (1) WO2005077413A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342280A1 (fr) * 1998-09-08 2000-03-16 Henry Ford Health System Methode de detection, de prevention et de traitement de troubles renaux par modulation, regulation et inhibition du facteur de croissance du tissu conjonctif
EP1891109A1 (fr) 2005-05-05 2008-02-27 Fibrogen, Inc. Traitements des maladies cardio-vasculaires
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
MX2009006768A (es) * 2006-12-22 2009-08-31 Bellus Health Int Ltd Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
EP2190433A2 (fr) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Thérapie pour complications du diabète
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
KR101762734B1 (ko) 2008-08-25 2017-07-28 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
CA2825059A1 (fr) 2011-02-02 2012-08-09 Excaliard Pharmaceuticals, Inc. Procede de traitement de cheloides ou de cicatrices hypertrophiees a l'aide de composes antisens ciblant un facteur de croissance de tissu conjonctif (ctgf)
CN105873608A (zh) 2013-11-28 2016-08-17 杰特有限公司 治疗肾病的方法
EP3665705A1 (fr) 2017-08-08 2020-06-17 Fresenius Medical Care Holdings, Inc. Systèmes et procédés de traitement et d'estimation de la progression d'une maladie rénale chronique
JP7152072B2 (ja) * 2018-07-31 2022-10-12 レモネックス インコーポレイテッド Ｃｔｇｆ発現抑制用組成物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
TW202110880A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 抗結締組織生長因子抗體及其應用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
WO1999033878A1 (fr) 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
AU4976599A (en) 1998-07-08 2000-02-01 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2342280A1 (fr) * 1998-09-08 2000-03-16 Henry Ford Health System Methode de detection, de prevention et de traitement de troubles renaux par modulation, regulation et inhibition du facteur de croissance du tissu conjonctif
CN1332801A (zh) 1998-11-06 2002-01-23 法布罗根公司 结缔组织生长因子(ctgf)及应用方法
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
CA2354422A1 (fr) * 1998-12-14 2000-06-22 University Of Miami Fragments de facteur de croissance du tissu conjonctif, et methodes et utilisations correspondantes
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
ATE526041T1 (de) 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
EP2221054A1 (fr) 2002-04-30 2010-08-25 Alcon, Inc. Inhibiteurs de CDK pour abaisser la pression intraoculaire
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP1687410A4 (fr) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Oligonucleotides antisens optimises pour cibler le rein

Also Published As

Publication number Publication date
HK1095762A1 (en) 2007-05-18
EP1977762A1 (fr) 2008-10-08
US20050214294A1 (en) 2005-09-29
CN101884789A (zh) 2010-11-17
CA2555789A1 (fr) 2005-08-25
ATE400297T1 (de) 2008-07-15
DE602005008013D1 (de) 2008-08-21
NZ549784A (en) 2008-06-30
WO2005077413A1 (fr) 2005-08-25
IL177437A0 (en) 2006-12-10
AU2005212371B2 (en) 2010-05-13
AU2005212371A1 (en) 2005-08-25
EP1715890B1 (fr) 2008-07-09
US20100291098A1 (en) 2010-11-18
PT1715890E (pt) 2008-10-17
US8314059B2 (en) 2012-11-20
EP1715890A1 (fr) 2006-11-02
ES2311973T3 (es) 2009-02-16
IL177437A (en) 2013-06-27
PL1715890T3 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
DK1715890T3 (da) CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
WO2006078463A3 (fr) Methode de traitement de maladie cardio-vasculaire
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200901211A1 (ru) Антигены белка с5 и их применение
EP1958648A4 (fr) Procede therapeutique visant les troubles de la coagulation sanguine
DK1889920T3 (da) In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
ATE557102T1 (de) Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin